Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence

被引：0
|
作者：
Chabre, Olivier [1 ]
Muller, Marie [2 ]
Cristante, Justine [1 ]
Cracowski, Jean-Luc [3 ]
Gay, Emmanuel [4 ]
机构：
[1] Univ Grenoble Alpes, CHU Grenoble Alpes, CEA,UGA, Unite Mixte Rech,Serv Endocrinol,INSERM,UMR 1036, F-38000 Grenoble, France
[2] CHU Grenoble Alpes, Serv Endocrinol, Grenoble, France
[3] Grenoble Alpes Univ, Pharmacovigilance Dept, INSERM, UMR 1300,Lab HP2, Grenoble, France
[4] Univ Grenoble Alpes, CHU Grenoble Alpes, Serv Neurochirurg, Grenoble, France
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2022年 / 10卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：384 / 385
页数：2
相关论文
共 50 条
  • [1] Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Reply
    Fleseriu, Maria
    Castinetti, Frederic
    Gadelha, Monica
    Giustina, Andrea
    Lacroix, Andre
    Melmed, Shlomo
    Newell-Price, John
    Pivonello, Rosario
    Reincke, Martin
    Biller, Beverly M. K.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (06): : 385 - 387
  • [2] Osilodrostat for the treatment of Cushing's disease
    Rasool, Syeda
    Skinner, Brian W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (09) : 1099 - 1106
  • [3] Osilodrostat (Isturisa) for Cushing's Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2021, 63 (1617): : 21 - 23
  • [4] Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease
    Paton, D. M.
    DRUGS OF TODAY, 2020, 56 (10) : 643 - 654
  • [5] Randomized Trial of Osilodrostat for the Treatment of Cushing Disease
    Gadelha, Monica
    Bex, Marie
    Feelders, Richard A.
    Heaney, Anthony P.
    Auchus, Richard J.
    Gilis-Januszewska, Aleksandra
    Witek, Przemyslaw
    Belaya, Zhanna
    Yu, Yerong
    Liao, Zhihong
    Ku, Chih Hao Chen
    Carvalho, Davide
    Roughton, Michael
    Wojna, Judi
    Pedroncelli, Alberto M.
    Snyder, Peter J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (07): : E2882 - E2895
  • [6] COVID-19 infection in a patientwith Cushing's disease on osilodrostat treatment
    Boguslawska, Anna
    Minasyan, Mari
    Hubalewska-Dydejczyk, Alicja
    Gilis-Januszewska, Aleksandra
    ENDOKRYNOLOGIA POLSKA, 2023, 74 (03) : 342 - 343
  • [7] Osilodrostat oral tablets for adults with Cushing's disease
    Martino, Marianna
    Aboud, Nairus
    Lucchetti, Beatrice
    Salvio, Gianmaria
    Arnaldi, Giorgio
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2022, 17 (02) : 99 - 109
  • [8] Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease
    Dougherty, John A.
    Desai, Divya Sanjaykumar
    Herrera, Javier Barrios
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (08) : 1050 - 1060
  • [9] Osilodrostat for the Treatment of Cushing's Disease: Growing Evidence in the Treatment of Rare Endocrine Diseases Comment
    Tabarin, Antoine
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (09): : E3961 - E3962
  • [10] Osilodrostat in Cushing's disease: the management of its efficacy and the pitfalls of post-surgical results
    Antonini, Simone
    Brunetti, Alessandro
    Zampetti, Benedetta
    Boeris, Davide
    Saladino, Andrea
    Cesare Cozzi, Renato
    ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2022, 2022
12345